Company

Potentia Ltd.

Potentia Therapeutics develops an antibody-oligonucleotide platform for peripheral nervous system disorders.

About

Founded in 2022, Potentia Therapeutics is based in Israel. Its Antibody-Oligonucleotide Conjugate platform combines antibody targeting with siRNA gene silencing. The lead program targets Charcot-Marie-Tooth disease 1A (CMT1A). In May 2026, Potentia Ltd. raised USD 0.90 million in seed funding from Peregrine Ventures.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in